← Leaderboards
Craig S Nunemaker
University Of Virginia
$3,563,425
Attributed
$4,701,202
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $740.9K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,701,202 · 5
By mechanism
R42$1,975,581 · 1
R01$1,648,874 · 1
R15$453,000 · 1
K01$323,773 · 1
R41$299,974 · 1
Top collaborators
- Shiyong Wu3 shared
- Veronica Andrea Bahamondes Lorca1 shared
Most similar at University Of Virginia
Same institution · by research overlap
- Sasanka Ramanadham$7,414,754
- Hui Li$8,132,942
- Raj Paul Wadwa$874,998
- Marc D Breton$12,156,787
- William A Petri$62,342,757
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventCellsIsletBeta CellIn VitroLeadInsulin SecretionInsulinDiabetes MellitusNon-Insulin-Dependent Diabetes MellitusCytokineInflammatoryIslets Of LangerhansInsulin-Dependent Diabetes MellitusDoseAffectStructure Of Beta Cell Of IsletBaseCalciumAmericanIn VivoMetabolic DiseasesImmuneCell Death
Grant awards (15)
A dual-acting small molecule for the treatment of type 1 diabetes$625,501
R42 · FY2025 · DK
A dual-acting small molecule for the treatment of type 1 diabetes$740,897
R42 · FY2024 · DK
A dual-acting small molecule for the treatment of type 1 diabetes$609,183
R42 · FY2023 · DK
A dual-acting small molecule for the treatment of type 1 diabetes$299,974
R41 · FY2021 · DK
Reducing Glycolytic Activity to Restore Normal Islet Glucose Sensing in Early Type 2 Diabetes$453,000
R15 · FY2019 · DK · contact PI
Low-grade Inflammation, Cytokines, and Beta-Cell Dysfunction in Type 2 Diabetes$320,056
R01 · FY2015 · DK · contact PI
Low-grade Inflammation, Cytokines, and Beta-Cell Dysfunction in Type 2 Diabetes$7,787
R01 · FY2015 · DK · contact PI
Low-grade Inflammation, Cytokines, and Beta-Cell Dysfunction in Type 2 Diabetes$334,950
R01 · FY2014 · DK · contact PI
Low-grade Inflammation, Cytokines, and Beta-Cell Dysfunction in Type 2 Diabetes$323,228
R01 · FY2013 · DK · contact PI
Low-grade Inflammation, Cytokines, and Beta-Cell Dysfunction in Type 2 Diabetes$334,950
R01 · FY2012 · DK · contact PI
Low-grade Inflammation, Cytokines, and Beta-Cell Dysfunction in Type 2 Diabetes$327,903
R01 · FY2011 · DK · contact PI
Assessing and Improving Pancreatic Islet Viability and Function$109,957
K01 · FY2010 · DK · contact PI
Assessing and Improving pancreatic islet viability and function$107,541
K01 · FY2009 · DK · contact PI
Assessing and Improving pancreatic islet viability and function$1,080
K01 · FY2009 · DK · contact PI
Assessing and Improving pancreatic islet viability and function$105,195
K01 · FY2008 · DK · contact PI